The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. by Caproni, M et al.
These articles have been accepted for publication in the British Journal of Dermatology and are 
currently being edited and typeset. Readers should note that articles published below have been 
fully refereed, but have not been through the copy-editing and proof correction process. Wiley-
Blackwell and the British Association of Dermatologists cannot be held responsible for errors or 
consequences arising from the use of information contained in these articles; nor do the views and 
opinions expressed necessarily reflect those of Wiley-Blackwell or the British Association of 
Dermatologists 
This article is protected by copyright. All rights reserved. 
 
Accepted Date : 27-Dec-2014 
Article type      : Research Letter 
 
The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum 
 
M. Caproni,1,* E. Antiga, 1,* W. Volpi,1 A. Verdelli,1 L. Venegoni,2 P. Quaglino,3 P. Fabbri,1 A.V. 
Marzano.2 
1Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, 
Florence, Italy 
2Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, 
Unità Operativa di Dermatologia, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico – 
Milan, Italy 
3Department of Biomedical Sciences and Human Oncology, 1st Dermatologic Clinic, University of 
Turin, Turin, Italy 
*These authors contributed equally to the preparation of the manuscript 
Corresponding author: 
Dr. Emiliano Antiga 
Department of Surgery and Translational Medicine, Section of Dermatology 
University of Florence 
Viale Michelangelo 41 
This article is protected by copyright. All rights reserved. 
50125 Florence, Italy 
Phone: +39 055 6939664 
Fax: +39 055 6939598 
e-mail: emiliano.antiga@unifi.it 
 
Funding: The study was funded by a grant Ministry of Instruction, University and Research of the 
Italian Government within the funding program PRIN 2008 (project code: 2008EW3FHK). 
 
Conflict of interests: None 
Keywords: pyoderma gangrenosum, Sweet’s syndrome, regulatory T cells, T helper 17 cells 
 
Pyoderma gangrenosum (PG) is a rare, inflammatory skin disease that, together with other 
conditions such as Sweet’s syndrome (SS), is included within the group of neutrophilic dermatoses.1 
Although its pathogenesis remains poorly understood,2 the treatments with the best clinical 
evidence are tumor necrosis factor (TNF)-inhibitors, high-dose systemic corticosteroids and 
cyclosporine, suggesting the pivotal role of inflammatory pathways in the development of PG. 
Interestingly, recent studies highlighted the role of T helper 17 (Th17) cells in neutrophilic 
dermatoses,2 and an increase of IL-173 and IL-234 expression was found in PG lesions.  
Together with Th17 cells, regulatory T cells (Tregs) play a major role in human disease.5 Accordingly, 
recent reports suggest that controlling the balance between Treg and Th17 cells may be a promising 
therapeutic strategy for inflammatory diseases.6 However, no data are present in the literature 
about Tregs in PG.  
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In this study, we investigated the proportions of Tregs and Th17 cells in the skin of 15 PG patients (7 
males, 8 females; age range 27-69 years), not on immunosuppressive treatment nor topical steroids 
for at least 4 weeks prior to entering the study. 
As control, skin samples from 5 SS patients (2 males, 3 females; age range 31-64 years) and 6 normal 
subjects (NS) (3 males, 3 females; age range 28-59 years) were collected. 
The trial was approved by ethical committee and conducted according to the Declaration of Helsinki. 
All the patients and controls provided written informed consent. 
Treg and Th17 markers were analysed by immunohistochemistry using monoclonal antibodies (mAb) 
anti-CD4 (1:20; Dako, Copenhagen, Denmark), anti-CD25 (1:25; Histo-Line Laboratories, Milan, Italy), 
anti-CD161 (1:80; AbD Serotec, Oxford, UK), anti-FoxP3 (1:80; Abcam, Cambridge, UK), anti-IL10 
(1:300; Dako), anti-IL-17 (1:1000; Abcam), anti-RORγt (1:2000; R&D Systems, Minneapolis, MN, USA), 
anti-TGFβ1 (1:2000; Abcam), as described previously.7 
The stained cells were counted in three consecutive microscopic fields (400×). Furthermore, 
FOXP3+/CD4+, TGF-β+/CD4+, IL-10+/CD4+ and RORγt+/CD4+ cell ratios were calculated. The results 
were analysed with Mann-Whitney U test and considered significant with a p value <0.05. 
In PG and SS, CD4+ and CD25+ cells were located in the whole dermis with some cells scattered in the 
epidermis (Fig. 1a,b,d,e). The number of CD4+ cells in PG was significantly higher than in SS 
(p=0.0003), while no differences were found for CD25+ cells. By contrast, CD4+ and CD25+ cells were 
significantly less represented in NS than in the other two groups (p<0.0001) (Fig. 2a).  
Some FOXP3+ cells were detected within the superficial dermis of patients with PG (Fig. 1g); their 
number was higher than in NS (p=0.004), but lower than in SS (p=0.0001) (Fig. 2a). Interestingly, the 
FOXP3+/CD4+ cell ratio was significantly lower in PG compared to SS (p<0.0001) and NS (p<0.0001) 
(Fig. 2a).  
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Some IL-10+ cells were found in PG superficial dermis (Fig. 1j); their number was significantly lower 
than in SS (p < 0.0001) and higher than in NS (p < 0.0001). Moreover, the IL-10/CD4+ cell ratio was 
reduced in PG than in SS and NS (p < 0.0001 and p = 0.03, respectively) (Fig. 2a). 
TGF-β staining was diffusely distributed within the superficial and medium dermis in PG and SS. 
Moreover, some TGF-β+ cells could be detected in the same areas (Fig. 1m,n). Their number was 
similar in both PG and SS. By contrast, the TGF-β+/CD4+ cell ratio was significantly reduced in PG (p = 
0.01). Moreover, although NS showed a lower number of TGF-β+ cells than PG (p < 0.0001) and SS (p 
< 0.0001), their TGF-β+/CD4+ cell ratio was significantly higher (NS vs PG: p = 0.001; NS vs SS: p = 
0.0001) (Fig. 2a). 
Regarding Th17 markers, RORγt+ cells were distributed in the upper dermis in PG (Fig. 1p); 
their number was similar to that found in SS. By contrast, the RORγt+/CD4+ ratio was 
significantly lower in PG than in SS (P = 0.008) (Fig. 2a). As expected, no RORγt expression 
was found in NS. The numbers of both CD161+ and IL-17+ cells, that were predominantly 
distributed in the superficial and medium dermis (Fig. 1s,t), were similar in PG and SS, while 
no CD161 nor IL-17 expression was detected in NS (Fig. 2a). 
Finally, in order to quantify the balance between Tregs and Th17 cells, we calculated the 
ratio between FOXP3 and RORγt, that was significantly lower in PG than in SS (p < 0.0001) 
(Fig. 2b). 
Our study demonstrated a reduced proportion of Tregs in PG skin, that may be responsible for an 
impairment of the suppressive activity, leading to the development of the lesions. Interestingly, Treg 
reduction was not found in SS, where the skin inflammation is less strong and the tissue damage 
milder.  
Accordingly, we found significantly reduced IL-10+/CD4+ and TGF-β+/CD4+ cell ratios in PG. IL-10 and 
TGF-β are involved in the biology of Tregs, and their defective signaling is associated with 
This article is protected by copyright. All rights reserved. 
inflammatory conditions.8-10 In agreement with our results, PBMCs from patients with PAPA 
syndrome (pyogenic sterile arthritis, PG, and acne) showed a diminished production of IL-10 after 
stimulation, suggesting an impairment of IL-10 pathway.11  
As a result, in PG, the impaired T cell regulation due to the reduction of Tregs and of the regulatory 
cytokines may allow the uncontrolled activation of effector T cells, such as Th17 cells.  
Interestingly, in PG skin, we found augmented numbers of Th17 cells, that may play a role in the 
disease via the recruitment of neutrophils and monocytes,12 and the induction of MMPs.13 
Accordingly, some Authors reported the effectiveness of therapies targeting the Th17 pathway in 
the treatment of PG.4,14 In this view, our findings may pave the way to the use of novel Th17-
oriented therapies such as IL-17 antagonists for PG therapy. 
Finally, we found an impairment of the balance between Tregs and Th17 cells in PG but not in SS, 
that could explain the most severe clinical course of the former. Interestingly, a reduced ratio of 
Tregs to Th17 cells was recently found even in patients with inflammatory bowel diseases,15 that are 
often associated to PG, suggesting that common mechanisms could be implicated in immune system 
dysregulation in both conditions. 
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Legend to figures: 
Figure 1. Immunohistochemical staining for CD4, CD25 and FOXP3 as markers of Tregs (a-i), for the 
regulatory cytokines TGF-β and IL-10 (j-o), as well as for  the Th17 cell markers RORγt, CD161 and IL-
17 (p-x) in skin biopsy specimens from patients with pyoderma gangrenosum (PG) and Sweet’s 
syndrome (SS). Scale bar = 100 μm 
Figure 2. (a) Numbers of CD4+, CD25+, FOXP3+, TGF-β+, IL-10+, RORγt+, CD161+ and IL-17+ cells 
expressed as medians, as well as FOXP3/CD4, TGF-β/CD4, IL-10/CD4 and RORγt/CD4 cell ratios 
expressed as % of CD4+ cells in the inflammatory infiltrate of skin biopsy specimens from patients 
with pyoderma gangrenosum (PG), Sweet’s syndrome (SS) and normal subjects (NS).  
(b) FOXP3/RORγt cell ratios in the inflammatory infiltrate of skin biopsy specimens from patients 
with PG and SS. PG showed a significantly reduced ratio than SS. *: p<0.05. 
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Supplementary table 1. Clinical findings in 15 patients with pyoderma gangrenosum. 
N Sex Age 
(years) 
Disease 
duration 
(months) 
Disease severity 
(BSA%) 
Associated 
diseases 
Family history
1 M 65 6 12 Klinefelter Negative 
2 M 61 3 8 - Negative 
3 F 28 12 18 Cystic fibrosis Negative
4 M 30 18 6 IBD Negative 
5 F 35 10 5 - Negative 
6 F 30 4 8 IBD Negative 
7 M 67 3 20 - Negative
8 M 62 24 8 - Negative 
9 M 57 18 3 - Negative 
10 F 44 48 2 - Negative 
11 F 69 40 3 - Negative 
12 M 42 6 6 - Negative 
13 F 48 16 1 - Negative 
14 F 53 36 10 - Negative
15 F 38 36 6 - Negative 
IBD: inflammatory bowel disease 
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Supplementary table 2. Quantitative analysis on the numbers of positive cells for field (400X) in skin 
lesions of patients with pyoderma gangrenosum and Sweet’s syndrome, as well as in normal subjects 
as assessed by immunohistochemistry 
 PG SS NS 
CD4 103 [90.7-143.5] 69 [54-77] 4.5 [2-7] 
CD25 18.5 [14-23.2] 22 [17.5-27] 1.5 [0.25-2] 
FOXP3 11 [2.2-16] 19 [18-23.5] 1 [0-2] 
% FOXP3/CD4 8.5 [3-12.7] 28 [26-29] 25 [6.2-33.3] 
TGF-β 28 [23.7-35.2] 28 [24.5-31] 3 [1.25-4] 
% TGF-β/CD4 23.9 [18.9-27.3] 36.8 [32.64-43] 63.6 [50-73.2] 
IL-10 16 [11.2-18] 24 [18-27] 1 [0-1.75] 
% IL-10/CD4 14.3 [12.1-16.6] 30.4 [22.4-39.5] 20 [11.7-38] 
RORγt 15 [13-18] 16 [11.2-32.2] 0 [0-0] 
% RORγt/CD4 12.1 [8.3-22.1] 23.3 [17.4-40.8] 0 [0-0] 
CD161 32 [23.5-65.5] 27 [17.5-31.5] 0 [0-0] 
IL-17 20.5 [17-25.2] 17.5 [13.2-23.5] 0 [0-0] 
% FOXP3/RORγt 32.4 [13.1-76.4] 122.1 [67.3-156.2] 0 [0-0] 
Positive-cell counts are expressed as medians [25th–75th percentile]. 
PG, pyoderma gangrenosum; SS, Sweet’s syndrome; NS, normal subjects. 
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